secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2026-08-03T21:00:36+00:00
Accession:  0001104659-26-089839
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus and Indivior announce all-stock merger of equals to create CNS-focused biopharma company
--------------------------------------------------------------------------------

- All-stock merger of equals between Supernus and Indivior; combined company to have four established CNS/behavioral health franchises.
- Jack Khattar (Supernus CEO) to serve as CEO of combined company; transaction expected to close in Q4 2026.
- Combined portfolio includes SUBLOCADE (opioid use disorder), Qelbree (ADHD), Zurzuvae (postpartum depression), Onapgo and GOCOVRI (Parkinson's).
- Merger intended to create financial strength and flexibility for business development; integration planning to be structured.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000110465926089839/0001104659-26-089839-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000110465926089839/tm2622009d7_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-089839

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer